The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.

Without taking a firm position, the antitrust agency said Novo’s two-step deal structure may illegally sidestep requirements ...

Soleno shares fell double digits amid questions about the growth trajectory of its Prader-Willi drug. Elsewhere, a cancer ...

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.

Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s ...

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...